Animal treating antibody developer gets VC funding: Asia News Roundup

（the article has been updated to make the text concise and cohesive)

Here are the latest updates from Asia’s biotech and pharma sectors:

MabGenesis Secures Venture Capital Funding
Yokohama-based biotech company MabGenesis, which focuses on developing antibody drugs for animals, has successfully secured ¥470 million ($3M) in venture capital funding. The funding was provided by two VC funds in Japan, signaling growing interest in the animal health sector.
Source: Nikkei

FDA Restricts Certain Viatris Generic Drugs from Japan
The U.S. FDA has imposed restrictions on eleven generic drugs made by Viatris at a facility in the Central Indian state of Madhya Pradesh. The agency stated that these products will no longer be accepted into the U.S. market.
Source: Economic Times

JCR Pharmaceuticals' Orphan Drug Designation
Japan’s JCR Pharmaceuticals Co., Ltd. (TSE 4552) has announced that the Ministry of Health, Labour and Welfare (MHLW) of Japan granted orphan drug designation to its investigational drug JR-441. This drug is being developed for the treatment of mucopolysaccharidosis type IIIA (MPS IIIA, or Sanfilippo syndrome type A). JR-441 is a blood-brain barrier (BBB)-penetrating form of recombinant heparan N-sulfatase, utilizing the company’s proprietary J-Brain Cargo® technology.
Source: Company Release

Shionogi Ends JV with Ping An Insurance
Shionogi has dissolved its joint venture with Ping An Insurance, one of China’s major insurance companies. The details of the dissolution have not been fully disclosed.
Source: Company Release

StemRIM Doses First Patient in Phase 2 Trial for Redasemtide
StemRIM Inc. (TSE: 4599) has announced that the first patient has been dosed in a Phase 2 clinical trial for its experimental drug, Redasemtide. The drug is being tested for ischemic cardiomyopathy at Osaka University Hospital.
Source: Company Release